Resolvin D1 attenuates depressive-like behavior in LPS-challenged mice by promoting microglial autophagy

Inflammopharmacology. 2023 Aug;31(4):2061-2075. doi: 10.1007/s10787-023-01234-9. Epub 2023 Apr 27.

Abstract

It has been proven that neuroinflammation triggered by microglial activation is the pathogenesis of depression associated with sepsis. An endogenous lipid mediator known as resolvin D1 (RvD1) is known to have anti-inflammatory effects in a sepsis model. However, it remains unknown if the effects of RvD1 on inflammatory responses are regulated by microglial autophagy. The current study investigated the role of RvD1-induced microglial autophagy in neuroinflammation. The findings showed that RvD1 reverses LPS-induced autophagy inhibition in microglia. RvD1 treatment significantly inhibits inflammatory responses by preventing NF-κB nuclear translocation and microglial M1 phenotypic transition. RvD1 exhibits an attenuation of neurotoxicity in both in vivo and in vitro models of sepsis. Following RvD1 injection, depressive-like behaviors in SAE mice were significantly improved. Notably, the aforesaid effects of RvD1 were eliminated by 3-MA, demonstrating that microglial autophagy was modulated. In conclusion, our findings shed new light on the involvement of microglial autophagy in SAE and emphasize the potential benefits of RvD1 as a promising therapeutic agent in the treatment of depression.

Keywords: Autophagy; Depression; Neuroinflammation; Neurotoxicity; Resolvin D1; Sepsis.

MeSH terms

  • Animals
  • Lipopolysaccharides / pharmacology
  • Mice
  • Microglia
  • Neuroinflammatory Diseases
  • Sepsis*
  • Signal Transduction*

Substances

  • Lipopolysaccharides
  • resolvin D1